Broad cell-based activity of drugs can be assessed via proliferation assays in a panel of cancer cell lines. The cancer cell lines in the Oncolines™ panel are from diverse tumour tissue origin and have been characterized with regard to the mutation status of more than hundred cancer-causing genes and by the expression of more than eighteen thousand genes. The drug sensitivity of the cell lines is determined in cell proliferation assays and is correlated to the cancer gene mutation status of the cell lines, yielding novel candidate drug sensitivity biomarkers as shown by Uitdehaag et al. 2019.
These biomarkers are used as selection markers for patient stratification (Zaman et al., 2017), while the drug sensitivity fingerprint of compounds in the entire Oncolines™ cell panel is used for comparative analyses with other anti-cancer agents, described by Uitdehaag et al. 2016, and for mechanism-of-action studies by Libouban et al., 2017. The Oncolines™ cell lines are also the basis of drug combination screens, as described by Uitdehaag et al. 2015.